<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053933</url>
  </required_header>
  <id_info>
    <org_study_id>B300201938708</org_study_id>
    <nct_id>NCT04053933</nct_id>
  </id_info>
  <brief_title>Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL</brief_title>
  <acronym>Be-QUALMS</acronym>
  <official_title>A Multicenter Observational Belgian Study Assessing the Impact of Newly Started Treatment on the QOL in Patients Suffering From Myelodysplastic Syndromes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study type An observational study conducted in different hematological centers in Belgium.

      Study objectives

      Primary objective:

      To assess the impact of newly started treatments on the QOL of patients suffering from
      myelodysplastic syndromes.

      Secondary objectives:

        -  To assess the impact of newly started therapy on disease perception in MDS patients

        -  To study the relation between disease perception and quality of life

        -  To examine which clinical and disease specific factors determine QOL in MDS patients

        -  Collect information on the transfusion threshold in Belgian hematological centers and
           evaluate the impact on quality of life.

        -  To evaluate whether changes in QOL are related to hematological respons.

      Study design

        -  Newly diagnosed MDS patients who are about to start a treatment or previously diagnosed
           MDS patients who are starting with a new line of therapy.

        -  QOL assessment with the QUALMS.

        -  Disease perception measurement using the B-IPQ.

        -  Measurement at diagnosis/before start of therapy, at 4 weeks, 12 weeks, and at 24 weeks
           into treatment.

      Study endpoints

      Primary endpoint:

      Change in QUALMS score at visit timepoints 4 - 12 - 24 weeks after the start of a new
      treatment.

      Secondary endpoint:

        -  Change in B-IPQ score at visit timepoints 4 - 12 - 24 weeks after the start of a new
           treatment

        -  Association between B-IPQ and QUALMS score.

        -  Association between clinical and disease specific factors and QUALMS score

        -  Association between transfusion threshold and QUALMS score.

        -  Association between hematological response and QUALMS score

      Summary of eligibility criteria

        -  Adult patients with a new diagnosis of MDS (according to WHO 2016 definitions (3) or
           known patients with MDS who are about to start a new treatment.

        -  Signed informed consent.

        -  Patients enrolled in an unblinded interventional therapeutic trial are eligible.

      Exclusion criteria

        -  Patients with acute leukemia defined as &gt;20% bone marrow blasts.

        -  Patients suffering from an overlap syndrome myelodysplastic/myeloproliferative disease.

        -  Patients in post allogeneic transplant setting.

        -  Patients enrolled in a blinded interventional therapeutic trial.

        -  Patients starting with multiple treatments under investigation at the same moment apart
           from intensive chemotherapy.

        -  Newly diagnosed patients who do not start with treatment.

        -  Patients who started a previous treatment less then 12 weeks ago apart from packed cell
           transfusion (up to 4 weeks allowed).

        -  Diagnosis of any previous or concomitant malignancy except when the patient successfully
           completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative
           intent for this malignancy at least 3 months prior to inclusion.

        -  Patients refusing to sign informed consent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Change in QUALMS-score</measure>
    <time_frame>6 months</time_frame>
    <description>Change in quality of life-score after the start of a new MDS related treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IPQ-score</measure>
    <time_frame>6 months</time_frame>
    <description>Change of ilness perception score after the start of a new MDS related treatment</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Patients treated with ESA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with 5'azacitidin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with deferoxamine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with deferasirox</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with transfusion only</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with lenalidomide</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with intensive chemotherapy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from myelodysplastic syndromes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients with myelodysplastic syndromes defined by WHO 2016 criteria
             that are about to start treatment.

          -  Patients with a known diagnosis of MDS, irrespective of IPSS and irrespective of time
             of diagnosis that are about to start a new therapy.

          -  Signed informed consent

        Exclusion criteria

          -  Patients with acute leukemia defined as &gt;20% bone marrow blasts.

          -  Patients suffering from a myelodysplastic/myeloproliferative overlap syndrome. In this
             case the disease has both dysplastic and proliferative features but cannot be properly
             categorized to either group. This category includes chronic myelomonocytic leukemia
             (CMML), juvenile myelomonocytic leukemia (JMML), atypial chronic myeloid leukemia
             (aCML) and myelodysplastic/myeloproliferative disease unclassifiable.

          -  Patients in post allogeneic transplant setting.

          -  Patients enrolled in a blinded interventional therapeutic trial.

          -  Patients starting with multiple MDS treatments at the same moment apart from intensive
             chemotherapy.

          -  Newly diagnosed patients who do not start with treatment.

          -  Patients who started a previous MDS related treatment less then 4 weeks ago.

          -  Patients who started a previous MDS related treatment less then 12 weeks ago apart
             from packed cell transfusions.

          -  Diagnosis of any previous or concomitant malignancy except when the patient
             successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy)
             with curative intent for this malignancy at least 3 months prior to inclusion.

          -  Patients refusing to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zwi Berneman, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bert Heyrman, MD</last_name>
    <phone>+32.3.280.34.59</phone>
    <email>bert.heyrman@zna.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erwin Janssen, MSc</last_name>
    <email>be.qualms@zna.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imelda</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Pauwels</last_name>
      <email>ann.pauwels3@imelda.be</email>
    </contact>
    <investigator>
      <last_name>Helena Maes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ KLINA</name>
      <address>
        <city>Brasschaat</city>
        <state>Antwerpen</state>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>datanurse.onco@klina.be</email>
    </contact>
    <investigator>
      <last_name>Stef Meers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Dimpna Ziekenhuis Geel</name>
      <address>
        <city>Geel</city>
        <state>Antwerpen</state>
        <zip>2240</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hadewijch.desamblanx@ziekenhuisgeel.be</email>
    </contact>
    <investigator>
      <last_name>Hadewijch Desamblanx</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heilig Hart Ziekenhuis</name>
      <address>
        <city>Lier</city>
        <state>Antwerpen</state>
        <zip>2500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Mostmans</last_name>
      <email>eva.mostmans@hhzhlier.be</email>
    </contact>
    <investigator>
      <last_name>Ann Van De Velde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale De Graef</last_name>
      <email>studies.hematologie@uza.be</email>
    </contact>
    <investigator>
      <last_name>Sebastien Anguille, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Jolimont</name>
      <address>
        <city>La Louvière</city>
        <state>Henegouwen</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petre Hélène</last_name>
    </contact>
    <contact_backup>
      <last_name>helene.petre@jolimont.be</last_name>
    </contact_backup>
    <investigator>
      <last_name>Selim Sid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Mons Hainaut</name>
      <address>
        <city>Mons</city>
        <state>Henegouwen</state>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Catherine Gérard</last_name>
      <email>annecatherine.gerard@chrmh.be</email>
    </contact>
    <investigator>
      <last_name>Dominique Boulet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <state>Henegouwen</state>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>recherche.clinique@hap.be</email>
    </contact>
    <investigator>
      <last_name>Caroline Jacquy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - UCL Namur site Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Marcin</last_name>
      <email>catherine.marcin@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Carlos Graux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saskia Baert</last_name>
      <email>saskia.baert@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Domoniek Mazure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <state>Oost Vlaanderen</state>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goel Wallays</last_name>
      <email>goele.wallays@aznikolaas.be</email>
    </contact>
    <investigator>
      <last_name>Isabelle Vande Broek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <state>Vlaams Brabant</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne De Meuter</last_name>
    </contact>
    <investigator>
      <last_name>Sebastian Wittnebel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Vlaams Brabant</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Hoedemaekers</last_name>
    </contact>
    <investigator>
      <last_name>Ann De Becker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eline Orlic</last_name>
      <email>eline.orlic@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Marielle Beckers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Vlaams Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Masson</last_name>
      <email>marie.masson@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Marie-Christiane Vekemans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <state>West Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas De Fauw</last_name>
      <email>thomas.defauw@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Dominik Selleslag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan Oostende</name>
      <address>
        <city>Oostende</city>
        <state>West Vlaanderen</state>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Lobbestael</last_name>
      <email>nlobbestael@azdamiaan.be</email>
    </contact>
    <investigator>
      <last_name>Achiel Van Hoof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Janssen</last_name>
      <email>erwin.janssen@zna.be</email>
    </contact>
    <investigator>
      <last_name>Bert Heyrman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Claeys</last_name>
      <email>kris.claeys@gza.be</email>
    </contact>
    <investigator>
      <last_name>Jan Lemmens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Namur</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Leon</last_name>
      <email>christine.leon@chrsm.be</email>
    </contact>
    <investigator>
      <last_name>Jasmine Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BR Clinic Saint Pierre Ottignies</name>
      <address>
        <city>Ottignies-Louvain-la-Neuve</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Vanbellinghen</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Connerotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Zwi Berneman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>QUALMS</keyword>
  <keyword>MDS</keyword>
  <keyword>Be-QUALMS</keyword>
  <keyword>Quality of life</keyword>
  <keyword>QoL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT04053933/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

